Shattuck’s Pipeline is Targeting the TL1A/DR3 Pathway
Shattuck’s lead DR3 blocking antibody, SL-325, demonstrates superior inhibition and efficacy in preclinical assays over therapies targeting TL1A. SL-325 harnesses the power of high affinity, epitope specificity and critical Fc-silencing to block TL1A from engaging DR3 expressed on multiple immune cells that drive inflammation.
Developing potential first-in-class DR3 monospecific and bispecific antibodies
| Programs | Stage of Development | ||||
| Leads | Target(s) | Indications | Preclinical | IND-Enabling | Phase 1 |
|---|---|---|---|---|---|
| SL-325 | DR3 | IBD | |||
| SL-425 Extended Half-Life | DR3 | IBD | |||
| Bispecifics | DR3 x Undisclosed | Autoimmune | |||
| Lead | Target | Indication | Stage |
|---|---|---|---|
| SL-325 | DR3 | IBD | IND-Enabling |
| SL-425 | DR3 | IBD | Preclinical |
| Bispecifics | DR3 x Undisclosed | Autoimmune | Preclinical |
